Related Experiment Videos
Clinical pharmacokinetics of troglitazone
C M Loi1, M Young, E Randinitis
1Department of Pharmacokinetics, Dynamics and Metabolism, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. CHO-MING.LOI@WL.COM
Clinical Pharmacokinetics
|September 25, 1999
Summary
Troglitazone, an oral antidiabetic, shows linear pharmacokinetics and is suitable for once-daily dosing. Hepatic impairment significantly alters its metabolism, while interactions exist with certain medications and food.
Area of Science:
- Pharmacology
- Endocrinology
- Drug Metabolism
Background:
- Troglitazone is a thiazolidinedione agent for type 2 diabetes.
- It improves glycemic control.
- Understanding its absorption, metabolism, and interactions is crucial.
Purpose of the Study:
- To characterize the pharmacokinetics and metabolism of troglitazone.
- To identify factors influencing its disposition.
- To assess drug and food interactions.
Main Methods:
- Pharmacokinetic profiling in healthy individuals and patients with type 2 diabetes.
- Metabolite identification (sulfation, glucuronidation, oxidation).
- Interaction studies with food, cholestyramine, CYP3A substrates, and oral contraceptives.
Main Results:
- Rapid absorption; bioavailability 40-50%, enhanced by food.
- Linear pharmacokinetics (200-600 mg daily); half-life 7.6-24 hours.
- Hepatic impairment increases troglitazone and metabolite concentrations; cholestyramine reduces absorption; interactions with CYP3A substrates and oral contraceptives observed.
Conclusions:
- Troglitazone exhibits predictable pharmacokinetics suitable for daily dosing.
- Hepatic impairment necessitates caution due to altered drug concentrations.
- Significant drug interactions warrant careful co-administration management.